Key result
The antidepressive response to mirtazapine 30 mg/day in patients with post-MI depression was significantly correlated with a pronounced increase in sTNF-R1.
Why the study?
Does mirtazapine 30 mg/day alter inflammatory markers in patients with post-myocardial infarction depression?
RCT (n=50)
Double-blind
Does mirtazapine 30 mg/day alter inflammatory markers in patients with post-myocardial infarction depression?
The antidepressive efficacy of mirtazapine in post-myocardial infarction depression is associated with an increase in soluble TNF-R1, suggesting an inflammatory mechanism.
Answers are grounded in this paper and cite their sources.
Supports TNF pathway involvement in mirtazapine response post-MI; extends inflammatory mechanisms for future targeted trials.
BACKGROUND: Depressive disorder after myocardial infarction (MI) is associated with increased cardiac morbidity and mortality. Immune activity such as inflammation might be implicated as an underlying mechanism. The purpose of this study is to investigate whether the response to an antidepressant in post-MI depression is associated with changes of inflammatory markers in serum. METHODS: In a double-blind placebo-controlled study with mirtazapine 30 mg/day (50 patients), the antidepressive effect was related to immune activation parameters. The cytokines interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α), the soluble cytokine receptors sIL-6R, sTNF-R1 and sTNF-R2, and the inflammation-sensitive plasma proteins C-reactive protein and neopterin were assessed. RESULTS: Subgroup analyses revealed a highly significant correlation of pronounced sTNF-R1 increase with a decrease in depressive symptoms in antidepressant responders. CONCLUSION: Significant effects on inflammation accompany the therapeutic efficacy of mirtazapine in contrast to the therapeutic efficacy of placebo and the nontherapeutic efficacy of mirtazapine.
No takes yet. Share an insight, caveat, or question.
Tulner et al. (2011) conducted an RCT in Post-myocardial infarction depression (n=50). Mirtazapine vs. Placebo was evaluated on Correlation of inflammatory marker changes with a decrease in depressive symptoms. The antidepressive response to mirtazapine 30 mg/day in patients with post-MI depression was significantly correlated with a pronounced increase in sTNF-R1.
Synapse has enriched 10 related papers. Consider them for comparative context: